Pharmacy benefit managers inflated drug prices by $7.3B

Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug Prices
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark,
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in many prescription drug transa
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
Pharmacy Benefits Managers Netted Extra $7.3B by Inflating Drug Prices: FTC
A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare and commercial claims alike.
Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The report is the latest indictment of America’s broken healthcare system.
policymed.com2d
Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics
The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...
Investing3d
FTC report shows major PBMs mark up specialty drugs significantly
Investing.com -- The Federal Trade Commission (FTC) has released a report showing that the three largest pharmacy benefit managers (PBMs) in the industry have significantly marked up ...